Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nivalis Therapeutics, Inc. (NASDAQ:NVLS) as Shares Go In the Tank

Law firm announces investigation of Nivalis Therapeutics, Inc. (NASDAQ:NVLS).  Details in the article below.

NEW YORK, Nov. 29, 2016 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Nivalis Therapeutics, Inc. (“Nivalis” or the “Company”) (NASDAQ: NVLS). Such investors can obtain additional information and assist the investigation by visiting the firm’s site:

The investigation concerns whether Nivalis and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On November 28, 2016, Nivalis announced that its Phase 2 Trial of Cavosonstat was unsuccessful in meeting its primary endpoint to indicate a benefit in the absolute change in percent-predicted FEV1 (lung function) or in sweat chloride reduction at 12 weeks, compared to the placebo. Following this news, Nivalis stock dropped roughly 59% on intraday trading on November 29, 2016.

If you are aware of any facts relating to this investigation, or purchased Nivalis shares, you can assist this investigation by visiting the firm’s site: You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Original Source


Nivalis Therapeutics, Inc. (NASDAQ:NVLS) shares have moved -58.88% on the news thus far today and have traded in the range of $2.50 – 3.04 during the current session. In order to take a look at where the stock might be headed longer term, investors often look to research firms that cover the stock. Sell-side research firms currently have a consensus one-year price target of $23.75 on the stock.  This is according to brokerage analysts polled by Thomson Reuters First Call.  The sell-side analysts are projecting earnings per share of $-0.60 for the next fiscal quarter.  For the current year, analysts are predicting earnings of $-2.10 per share according to First Call.

Are Shares of Nivalis Therapeutics, Inc. (NASDAQ:NVLS) Ready to Explode?  Sign up to our Newsletter to be the First to Know

Sign up to get our Free Penny Stock Picks Before the Street!

In looking at where the stock is trading on a technical level, the stock is trading -60.23% away from its 50-day moving average of $6.46.  Based on the most recent available data, the equity is -72.82% off of its 52-week high of $9.45 and +2.80% away from its 52-week low which is $2.50.

Today, the stock opened at $2.87 and the last bid at the time of writing stood at $2.57.  During the session thus far, the equity dipped down to $2.50 and touched $3.04 as the high point.  Nivalis Therapeutics, Inc. (NASDAQ:NVLS) has a market cap of $39.95M and has seen an average daily volume of 74,769 over the past three months.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below.

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs.  Where quoted, past performance is not indicative of future performance.





Related posts

Leave a Comment